Imunofan
- Category
- Bioregulators
- Administration routes
- InjectableNasal
- Regulatory status
- Not FDA-approved
A synthetic hexapeptide marketed as an immune modulator for infection recovery and immune balance. Only immune normalization has moderate support; tissue repair, vaccine adjuvant use, epigenetic effects, and anti-tumor support are speculative, mechanism-only, and barely studied in humans. Safety evidence remains limited. Russian labeling lists individual intolerance and possible temporary exacerbation of chronic inflammatory foci. Not FDA-approved, and products sold online are unregulated.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Imunofan (also spelled Immunofan) is a synthetic hexapeptide with the amino acid sequence RDKVYR (Arg-Asp-Lys-Val-Tyr-Arg), marketed as an immunomodulatory agent. Like Cortexin, it is a registered pharmaceutical drug in Russia rather than just a dietary supplement. Imunofan was developed as a synthetic modification of the thymic hormone thymopoietin and is used clinically in Russia for immunodeficiency states, vaccine adjuvant activity, oncological support, and infectious disease management.
A 2020 study published in Molecules (MDPI, open access) investigated Imunofan's ability to stimulate skin cell proliferation and promote tissue repair. The study found that Imunofan displayed stability in aqueous solutions, exerted significant pro-proliferative activity (30-40% increase in fibroblast proliferation, 20-50% increase in keratinocyte proliferation), showed no cytotoxicity over a vast concentration range, and had no allergic properties. It also induced significant transcriptional responses including enhanced DNA demethylation gene activity. A 2025 study (PMID 41116267) evaluated solid-phase synthesized Imunofan as a vaccine adjuvant, finding clinically relevant adjuvant activity compared to Freund's adjuvant.
Imunofan is available as nasal spray, suppositories, and injectable solution in Russia. It has a well-defined molecular structure (unlike the polypeptide complex bioregulators), which has enabled more rigorous pharmacological characterization.
How it works in the body
A synthetic hexapeptide (arginyl-alpha-aspartyl-lysyl-valyl-tyrosyl-arginine) that modulates immune function at multiple levels. It restores the balance between Th1 and Th2 immune responses, stimulates antioxidant defense by increasing glutathione and ceruloplasmin levels, and enhances phagocytic activity without causing immune overstimulation.
Research overview
Imunofan has the most robust pharmacological characterization of any Khavinson-associated peptide, owing to its defined single-sequence structure (RDKVYR). The 2020 MDPI Molecules study provides detailed data on stability, cytotoxicity, pro-proliferative activity, and transcriptional effects. Key findings include: 30-40% increase in fibroblast proliferation, 20-50% increase in keratinocyte proliferation, enhanced DNA demethylation gene activity, activation of immune response/migration/chemotaxis genes in stem cells, and moderate tissue repair promotion in mouse ear pinna injury models (8-36% improvement). The 2025 adjuvant study (PMID 41116267) reports protection in vaccinated mice; human vaccine efficacy was not tested. Russian clinical literature describes extensive use in immunodeficiency, oncology (supportive care), and infectious diseases. The drug has been used clinically in Russia for over 25 years.
Who researches Imunofan?
Commonly researched by
People exploring tissue repair and injury recovery
Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.
People researching immune system support
Studied for immune modulation, antiviral, or antimicrobial properties.
People researching experimental oncology peptides
Studied for effects on cancer cell targeting or tumor biology in preclinical research.
Important considerations for
Those who are pregnant or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Anyone under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Those with Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Safety & interactions
Do not use if
Children under 2 under Russian nasal-spray labeling
AbsoluteThe Russian label permits use in older children; this does not establish FDA approval or comprehensive pediatric safety.
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(3)
Rated by level of concern
Allergic reaction
LowPMID 32585846; PMID 10377887
Potential immune modulation in autoimmune conditions
TheoreticalPMID 10377887; PMID 11764501
Injection site reactions (injectable form)
LowPMID 10377887; PMID 32585846
Interaction summary(8)
Rated by direction with this peptide
MRP/MDR-substrate chemotherapy (e.g. vincristine, anthracyclines, etoposide)
CautionModerateThe published pharmacology is explicitly bidirectional: Imunofan inhibited multidrug-resistance transport proteins during substrate transport but INCREASED their activity in the latent period, with >1000-fold greater inhibitory potency than other substrate analogues and a protein-kinase-C-dependent mechanism (PMID 17603672); the 2004 tumor-cell report is indexed title-only (PMID 15255157). Altered efflux could raise intracellular cytotoxic drug levels and toxicity, or conversely prime resistance - either outcome is clinically consequential. All data are preclinical; no human co-administration or drug-level study exists, and a net benefit has never been shown.
PMID 15255157; PMID 17603672
Radiotherapy and cytotoxic chemotherapy regimens (supportive use)
ProtectiveLowIn an endometrial adenocarcinoma series, adding Imunofan to radiation/chemoradiation was associated with fewer radiation-induced complications and restoration of lymphocyte subsets and neutrophil phagocytic activity (PMID 11764501), consistent with the review's claim of enhanced free-radical/oxidant inactivation and shortened radiation and toxic reactions (PMID 10377887). Evidence quality is low: a single small non-randomized, unblinded series with no independent replication, so 'protective' describes the reported direction, not a demonstrated effect.
PMID 11764501; PMID 10377887
Cyclosporine and other calcineurin-inhibitor immunosuppressants
CautionTheoreticalPharmacodynamic opposition only: an agent marketed to restore cell-mediated immunity and raise CD3+/CD4+/CD8+ counts runs against deliberate immunosuppression, which would matter in transplant recipients or patients on maintenance immunosuppression. No clinical, pharmacokinetic or drug-level data exist in either direction.
PMID 10377887; PMID 11764501
Systemic corticosteroids
CautionTheoreticalMechanism-based only: corticosteroids suppress the cell-mediated responses, cytokine signaling and neutrophil oxidative burst that Imunofan is reported to restore, so concurrent use would be expected to blunt its pharmacodynamic effect. No interaction study of any kind exists; this is inference from the mechanism review, not an observed interaction.
PMID 10377887
Fluoroquinolone antibiotics (moxifloxacin) in C. difficile infection
CautionTheoreticalIn vitro only, and concentration-dependent in both directions. Imunofan alone at 0.05-0.25 ug/ml showed antimicrobial activity against a toxigenic C. difficile strain, and maximum combined growth inhibition occurred at 1.5 ug/ml imunofan with 2.5x MIC moxifloxacin. Correction: the growth-stimulating range is moxifloxacin 0-1.5x MIC (not merely sub-MIC), and stimulation occurred regardless of imunofan concentration. The pairing therefore cannot be assumed beneficial at clinical exposures; no in vivo or human data.
PMID 32762196
Vaccines (as co-administered adjuvant)
SynergisticTheoreticalIn BALB/c mice (n=10/group), Imunofan co-administered with a chimeric E. coli O157:H7 antigen produced shedding reduction comparable to Freund's adjuvant despite markedly lower IgG titers. A single unreplicated mouse study published online-ahead-of-print in a low-tier journal; the lower antibody response means it could equally under-perform for antibody-dependent vaccines. No human vaccine co-administration data, and the effect on approved vaccine schedules is unknown.
PMID 41116267
Biologic immunosuppressants / anti-TNF and other cytokine-blocking therapy
CautionTheoreticalImunofan is reported to lower TNF and IL-6 while restoring cell-mediated immunity - an overlapping-but-opposing profile to cytokine blockade. Combining an immune-restorative peptide with biologic therapy for autoimmune disease has never been studied and could destabilize disease control. Pure mechanistic inference from a narrative review; no case reports or studies exist.
PMID 10377887
Antiretroviral and other chronic antiviral regimens (hepatitis B/C, opportunistic infection)
NeutralTheoreticalThe review describes Imunofan being used within combination therapy for chronic hepatitis B/C, brucellosis and opportunistic infections, reporting enhanced antiviral/antibacterial immunity - it does NOT report antiretroviral co-administration, drug levels or absence of pharmacokinetic interference. No formal interaction or drug-level study has been published for any antiviral, so a neutral interaction is assumed from uneventful concomitant use, not demonstrated.
PMID 10377887
Known risks(3)
Allergic reaction
LowThe 2020 study found no allergic response in its laboratory tests; it did not establish a clinical allergy rate.
Potential immune modulation in autoimmune conditions
ModerateAs an immunomodulator, Imunofan could theoretically affect autoimmune conditions. However, it is described as 'normalizing' rather than purely stimulatory.
Injection site reactions (injectable form)
LowMinor injection site reactions possible with IM/SC administration.
Drug interactions(3)
Immunosuppressants
Potential antagonism with immunosuppressive therapy; clinical monitoring required
Vaccines
Adjuvant activity demonstrated; may enhance vaccine immune response
Chemotherapy agents
Used as supportive therapy during chemotherapy in Russian oncology practice
Research & benefits
Evidence base
- Evidence Level
- Moderate Evidence (registered drug with published studies in international journals)
- Total Studies
- 30
- Human Participants
- 5000
Imunofan has the strongest evidence profile among Khavinson-associated peptides. It has a defined molecular structure enabling rigorous study, a 2020 MDPI publication with detailed in vitro and in vivo data, a 2025 adjuvant study, and decades of Russian clinical use as a registered pharmaceutical. The MDPI study provides Western-accessible peer-reviewed data on mechanism and efficacy. Russian clinical trials have enrolled thousands of patients across multiple indications.
Researched for(5)
Rated by confidence in the evidence
Immunomodulatory activity (immune system normalization)
MediumMultiple human studies, including one randomized trial, show immune parameter improvements.
PMID 10377887; PMID 11764501; PMID 20481041; PMID 20020612; PMID 8771665
Skin cell proliferation and tissue repair promotion
SpeculativeSingle 2020 study: boosted skin cell growth and wound closure in mice, no human data.
PMID 32585846
Vaccine adjuvant activity
SpeculativeSingle 2025 mouse study suggests adjuvant effect against one bacterial antigen, unreplicated.
PMID 41116267
DNA demethylation gene activation (epigenetic effects)
SpeculativeFibroblast study suggested altered DNA-demethylation gene activity, though results were inconsistent across genes.
PMID 32585846
Anti-tumor support (immune-mediated)
SpeculativeLimited to a small supportive-care study and unconfirmed preclinical mechanism data, not tumor outcomes.
PMID 11764501; PMID 15255157; PMID 17603672
Benefits(5)
Immunomodulatory activity (immune system normalization)
Russian pharmaceutical registration data; decades of clinical use
Skin cell proliferation and tissue repair promotion
Molecules 2020 (MDPI); fibroblast 30-40% increase, keratinocyte 20-50% increase
Vaccine adjuvant activity
PMID 41116267 (2025); solid-phase synthesized Imunofan vs. Freund's adjuvant
DNA demethylation gene activation (epigenetic effects)
Molecules 2020 (MDPI); transcriptional response analysis
Anti-tumor support (immune-mediated)
Russian oncology clinical data; Bespalov et al. tumor incidence reduction study
Key studies(2)
Imunofan -- RDKVYR Peptide -- Stimulates Skin Cell Proliferation and Promotes Tissue Repair
In vitro + in vivoCell lines + mouse modelsVariable (cell culture + wound healing timeline)Sawicka J, Dzierzynska MA, Wardowska A, Deptula M, et al.
Molecules (MDPI)
2020
Imunofan showed 30-40% fibroblast and 20-50% keratinocyte proliferation increase, no cytotoxicity, no allergic properties, enhanced DNA demethylation genes, and moderate tissue repair (8-36%) in mouse ear pinna injury model.
Solid-Phase Synthesized Imunofan Confers Clinically Relevant Protection using a Chimeric Protein Vaccine Candidate Against E. coli O157:H7 in BALB/c Mice
Comparative studyAnimal modelsVaccination protocolAuthors not fully retrieved
PubMed-indexed journal
2025
Solid-phase synthesized Imunofan demonstrated clinically relevant adjuvant activity comparable to Freund's adjuvant, supporting its use as a vaccine enhancer.
Regulation & availability
Why researchers look at it
Imunofan is the most pharmacologically characterized Khavinson-associated peptide, with a defined hexapeptide sequence, MDPI-published efficacy data, and decades of Russian clinical use. It bridges traditional bioregulator research with modern peptide pharmacology.
- Estimated cost
- $30-80/course (nasal spray or injection; available in Russia)
- FDA status
- Not FDA-approved; registered pharmaceutical in Russia; defined synthetic peptide structure
- WADA status
- Not listed on WADA Prohibited List; not evaluated by WADA
- Prescribability
- Registered drug in Russia; available by prescription in CIS countries; not approved in USA/EU
- Availability
- Available as nasal spray, rectal suppositories, and injectable solution in Russia. The defined synthetic structure means it can be produced by peptide synthesis. Not available through conventional channels in the USA or EU.
International status
EU
Not approved
US
Not approved; not available
CIS
Approved in multiple CIS countries
Russia
Registered pharmaceutical (approved for immunodeficiency, adjunct oncology)
Worldwide
Approved primarily in Russia
Regulatory timeline(4)
- 1990sDeveloped and registered as pharmaceutical in Russia
- 2000sWidely prescribed in Russian immunology and oncology practice
- 2020MDPI Molecules study on skin proliferation and tissue repair published
- 2025Adjuvant activity study published (PMID 41116267)
Sources & FAQs
Research sources(4)
Frequently asked questions(4)
What is Imunofan's chemical structure?
Imunofan is a synthetic hexapeptide with the sequence RDKVYR (Arg-Asp-Lys-Val-Tyr-Arg). It is a defined single-sequence molecule, unlike the complex polypeptide mixtures in most Khavinson bioregulators. This makes it more amenable to rigorous pharmacological study.
How is Imunofan administered?
In Russia, Imunofan is available as a nasal spray (for daily immunomodulation), rectal suppositories, and injectable solution (subcutaneous or intramuscular). The nasal spray form is most convenient for chronic use.
What conditions is Imunofan used for in Russia?
Imunofan is prescribed for immunodeficiency states, as adjuvant therapy in oncology (to support immune function during chemotherapy), in chronic infectious diseases, for vaccine enhancement, and in allergic conditions. It is also studied for wound healing and tissue repair applications.
Is Imunofan the same as thymopoietin?
No. Imunofan is a synthetic modification derived from a fragment of thymopoietin (a natural thymic hormone). It retains immunomodulatory activity but has been optimized for stability and clinical use.